<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104370">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133261</url>
  </required_header>
  <id_info>
    <org_study_id>7 day study</org_study_id>
    <nct_id>NCT02133261</nct_id>
  </id_info>
  <brief_title>BDx 7 Day ECG Patch: Electrode Adhesion Clinical Study</brief_title>
  <official_title>BDx 7 Day ECG Patch: Electrode Adhesion Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bardy Diagnostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bardy Diagnostics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn if a new 7 day patch ECG recording monitor
      can serve the same purpose as standard monitoring systems.  The new 7day patch is
      significantly smaller and lighter than previous ECG recorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this research is to evaluate ECG signal quality of the BDx 7 day ECG
      Patch heart monitor after 7 full days of wear, establishing that the device is safe and
      effective to wear for up to 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>adhesive performance/durability</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The study will evaluate adhesive performance/durability by evaluating the Signal Quality of ECG data on the subjects (5 men and 5 women) in accordance with the requirements of FDA's ECG Electrode Guidance (section 5.A.3)1 and the ANSI/AAMI EC-12 Disposable ECG electrode technical standard (sections 4.4 and 5.4)2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>human factors</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skin comfort or discomfort Device comfort Device stability and contact</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cardiac Patients</condition>
  <condition>ECG Monitoring</condition>
  <eligibility>
    <study_pop>
      <textblock>
        cardiac patients followed at the study site's location
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cardiac patient volunteers (5 male and 5 female)

        Exclusion Criteria:

          -  skin rash or infection over the sternum

          -  Sternal incision within 3 months from the date of enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gene Trobaugh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EvergreenHealth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gene Trobaugh, MD</last_name>
    <phone>360-802-5021</phone>
    <email>trobaughmd@live.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>EvergreenHealth</name>
      <address>
        <city>Enumclaw</city>
        <state>Washington</state>
        <zip>98022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gene Trobaugh, MD</last_name>
      <phone>360-802-5021</phone>
      <email>trobaughmd@live.com</email>
    </contact>
    <investigator>
      <last_name>Gene Trobaugh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
